Bellerophon Announces Top-line Results from Cohort 1 of the INOpulse® Phase 2b Clinical Trial for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Bellerophon Therapeutics, Inc. (BLPH)
Last bellerophon therapeutics, inc. earnings: 4/6 10:23 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.bellerophon.com
Company Research
Source: GlobeNewswire
WARREN, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced top-line results from Cohort 1 of the Company’s ongoing Phase 2b randomized, double-blind, placebo-controlled clinical study (iNO-PF) evaluating INOpulse® in patients with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). Statistically significant improvements in multiple clinically meaningful activity parameters as measured by a wearable medical-grade activity monitor (actigraphy) were observed: Subjects on pulsed inhaled nitric oxide (iNO) demonstrated an increase of 8% in moderate activity versus a 26% decrease for subjects on placebo (p=0.04)Subjects on iNO showed no decline in their overall activity levels versus a 12% decline for subjects on placebo (p=0.05) Wearable activity monitoring is designed to provide continuous objective real-world physical activity data an
Show less
Read more
Impact Snapshot
Event Time:
BLPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLPH alerts
High impacting Bellerophon Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
BLPH
News
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat